Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Shares Outstanding (Diluted Average) (2023 - 2025)

Goldenwell Biotech (GWLL) has disclosed Shares Outstanding (Diluted Average) for 3 consecutive years, with $96.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Diluted Average) changed 0.0% year-over-year to $96.4 million, compared with a TTM value of $96.4 million through Sep 2025, changed 0.0%, and an annual FY2024 reading of $99.0 million, changed 0.0% over the prior year.
  • Shares Outstanding (Diluted Average) was $96.4 million for Q3 2025 at Goldenwell Biotech, roughly flat from $96.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $99.0 million in Q4 2023 and bottomed at $96.4 million in Q2 2024.
  • Average Shares Outstanding (Diluted Average) over 3 years is $97.7 million, with a median of $97.7 million recorded in 2023.
  • Peak annual rise in Shares Outstanding (Diluted Average) hit 0.0% in 2024, while the deepest fall reached 0.0% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $99.0 million in 2023, then changed by 0.0% to $99.0 million in 2024, then dropped by 2.59% to $96.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for GWLL at $96.4 million in Q3 2025, $96.4 million in Q2 2025, and $99.0 million in Q1 2025.